General Atlantic LLC Akero Therapeutics, Inc. Transaction History
General Atlantic LLC
- $2.79 Billion
- Q4 2024
A detailed history of General Atlantic LLC transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, General Atlantic LLC holds 5,233,989 shares of AKRO stock, worth $197 Million. This represents 5.21% of its overall portfolio holdings.
Number of Shares
5,233,989
Previous 5,233,989
-0.0%
Holding current value
$197 Million
Previous $150 Million
3.03%
% of portfolio
5.21%
Previous 4.29%
Shares
2 transactions
Others Institutions Holding AKRO
# of Institutions
209Shares Held
67.5MCall Options Held
321KPut Options Held
558K-
Rtw Investments, LP New York, NY6.86MShares$258 Million3.11% of portfolio
-
Janus Henderson Group PLC London, X06.03MShares$227 Million0.09% of portfolio
-
Black Rock Inc. New York, NY5.59MShares$210 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.32MShares$163 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.7MShares$140 Million0.0% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $1.75B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...